VYCO — Vycor Medical Income Statement
0.000.00%
- $2.87m
- $3.78m
- $1.46m
- 65
- 63
- 40
- 57
Annual income statement for Vycor Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.39 | 1.14 | 1.39 | 1.22 | 1.46 |
Cost of Revenue | |||||
Gross Profit | 1.26 | 1.01 | 1.26 | 1.08 | 1.32 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.99 | 1.87 | 1.71 | 1.53 | 1.42 |
Operating Profit | -0.601 | -0.727 | -0.319 | -0.307 | 0.04 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.67 | -0.8 | -0.408 | -0.4 | -0.063 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.67 | -0.8 | -0.408 | -0.4 | -0.063 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -0.796 | -0.822 | -0.436 | -0.405 | -0.07 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.12 | -1.15 | -0.76 | -0.729 | -0.394 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.042 | -0.043 | -0.029 | -0.023 | -0.012 |